Clinical Trial Update: Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes [Phase 1, Phase 2]

View source ↗

Summary

Karolinska Institutet completed a Phase 1/2 trial evaluating an arginase inhibitor and its effect on microvascular endothelial function in Type 2 Diabetes Melli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Arginase inhibitor (investigational) (arginase inhibitor)

Snippet

Sponsor: Karolinska Institutet | Conditions: Type 2 Diabetes Mellitus | Phase 1, Phase 2 | Status: COMPLETED